In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, ChinaYiqun Li, Binghe Xu, Nilupai Abudureheiyimu et al.|Frontiers in Oncology|2022Cited by 119
Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trialZijing Wang, Xu B, Jiaxuan Liu et al.|Breast Cancer Research and Treatment|2021Cited by 22
Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in ChinaYiqun Li, Binghe Xu, Qiao Li et al.|The Breast|2020Cited by 21
Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancerQing Li, Binghe Xu, Jiani Wang et al.|Chinese Journal of Cancer Research|2020Cited by 11
Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, ChinaYiqun Li, Binghe Xu, Hongnan Mo et al.|The Breast|2021Cited by 10